Arch Pharmalabs Limited is a pharmaceutical company based in India, primarily engaged in the manufacturing and sale of Active Pharmaceutical Ingredients (APIs) and intermediates. Business SegmentsArch Pharmalabs operates across two primary verticals:Products: This segment includes the manufacture and sale of APIs and intermediates to both innovator and generic pharmaceutical companies in domestic and international markets. The company offers over 120 products across various therapeutic segments such as oncology, anti-diabetic, anti-hypertensive, and more.Services: The services include Contract Research and Manufacturing Services (CRAMS), which encompass custom synthesis, process development, analytical development, and clinical trial manufacturing.Market PresenceArch Pharmalabs has established nine multipurpose manufacturing facilities equipped with modern technologies.The company has formed strategic alliances with international firms like Codexis (USA) and DSM (Netherlands) to enhance its manufacturing capabilities and implement green chemistry initiatives.
| P&L Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 706 | 1309 | 1341 | - |
| Cost of Material Consumed | 444 | 1052 | 1062 | - |
| Gross Margins | 37.11 | 19.63 | 20.81 | - |
| Change in Inventory | 21 | -68 | -37 | - |
| Employee Benefit Expenses | 74 | 75 | 69 | - |
| Other Expenses | 892 | 73 | 67 | - |
| EBITDA | -725 | 177 | 180 | - |
| OPM | -102.69 | 13.52 | 13.42 | - |
| Other Income | 2853 | -1 | 1 | - |
| Finance Cost | 231 | 98 | 35 | - |
| D&A | 28 | 25 | 23 | - |
| EBIT | -753 | 152 | 157 | - |
| EBIT Margins | -106.66 | 11.61 | 11.71 | - |
| PBT | 1869 | 52 | 122 | - |
| PBT Margins | 264.73 | 3.97 | 9.1 | - |
| Tax (2021) | 0 | 0 | 0 | - |
| PAT | 1869 | 52 | 122 | - |
| NPM | 264.73 | 3.97 | 9.1 | - |
| EPS | 123.03 | 3.42 | 7.8 | - |
| Financial Ratios | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Operating Profit Margin | -102.69 | 13.52 | 13.42 | - |
| Net Profit Margin | 264.73 | 3.97 | 9.1 | - |
| Earning Per Share (Diluted) | 123.03 | 3.42 | 7.8 | - |
| Assets | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Fixed Assets | 926 | 879 | 820 | - |
| CWIP | 22 | 26 | 30 | - |
| Investments | 22 | 15 | 13 | - |
| Trade Receivables | 274 | 314 | 698 | - |
| Inventory | 772 | 699 | 681 | - |
| Other Assets | 346 | 385 | 173 | - |
| Total Assets | 2362 | 2318 | 2415 | - |
| Liabilities | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Share Capital | 151.92 | 151.92 | 156.48 | - |
| FV | 10 | 10 | 10 | - |
| Reserves | 81 | 452 | 681 | - |
| Borrowings | 1139 | 856 | 850 | - |
| Trade Payables | 456 | 337 | 266 | - |
| Other Liabilities | 534.08 | 521.08 | 461.52 | - |
| Total Liabilities | 2362 | 2318 | 2415 | - |
| Cash-Flow Statement | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| PBT | -891 | 52 | 124.6 | - |
| OPBWC | 154 | 181.64 | 182.17 | - |
| Change in Receivables | -12 | -43 | -384 | - |
| Change in Inventories | 30 | 73 | 18 | - |
| Change in Payables | 0 | 0 | 0 | - |
| Other Changes | 106 | -96.12 | 226.32 | - |
| Working Capital Change | 124 | -66.12 | -139.68 | - |
| Cash Generated From Operations | 278 | 115.52 | 42.49 | - |
| Tax | 0 | -0.18 | 0 | - |
| Cash Flow From Operations | 278 | 115.34 | 42.49 | - |
| Purchase of PPE | -8 | -16 | 2.4 | - |
| Sale of PPE | 0 | 0 | 0 | - |
| Cash Flow From Investment | -8 | -10.67 | -1.39 | - |
| Borrowing | -39 | -6.8 | -6.34 | - |
| Divided | 0 | 0 | 0 | - |
| Equity | 0 | 0 | 0 | - |
| Others From Financing | -231 | -98.33 | -34.75 | - |
| Cash Flow from Financing | -270 | -105.13 | -41.09 | - |
| Net Cash Generated | 0 | -0.46 | 0.01 | - |
| Cash at the Start | 3 | 3 | 2.76 | - |
| Cash at the End | 3 | 2.54 | 2.77 | - |
| Shareholding Pattern | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Arch Impex Private Limited | 36.47% | 36.47% | 25.24% | - |
| JM Financial Asset Reconstruction Company Limited | 26% | 26% | 35% | - |
| Arch Pharmachem Limited | 13.94% | 13.94% | 13.54% | - |
| Others | 23.59% | 23.59% | 25.81% | - |
